BRIEF-Cansino Biologics Says Recombinant Novel Coronavirus Disease Vaccine Approved For Trial

March 18 (Reuters) - Cansino Biologics Inc:

* RECOMBINANT NOVEL CORONAVIRUS DISEASE VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR CLINICAL TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)